Program
trosunilimab
Also written as “Trosunilimab” and “ABBV-382”.
Its studies are mostly in Crohn Disease · Acquired Immunodeficiency Syndrome, led by AbbVie.
Furthest: phase 2, since Sep 5, 20236 company-led studies, 3 open or runningNext primary completion: May 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 63 open or running | phase 2since Sep 5, 2023 | Sep 14, 2020 | May 2027phase 1 · NCT07925983 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 14, 2020First study: phase 1 study in Acquired Immunodeficiency SyndromeFirst studyNCT04554966 · 54 enrolled · United States, Puerto Rico
- Sep 5, 2023Phase 2 study in DiseaseNCT06032546 · 163 enrolled · United States, Belgium, Brazil and more
- Aug 8, 2024Phase 2 study in Crohn DiseaseNCT06548542 · 590 planned · United States, Austria, Belgium and more
- Oct 8, 2024Phase 1 study in Healthy VolunteerNCT06632938 · 24 enrolled · China
- Jul 7, 2026Phase 2 study in Crohn DiseaseNCT07697456 · 2,000 planned · United States, Canada, Israel and more
- Oct 21, 2026Phase 1 study in Healthy VolunteerNCT07925983 · 60 planned · United States
Ahead
- May 2027Primary completion: phase 1 study in Healthy VolunteerNCT07925983
- Jan 2030Primary completion: phase 2 study in Crohn DiseaseNCT06548542
- Oct 2031Primary completion: phase 2 study in Crohn DiseaseNCT07697456
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07925983Healthy Volunteer · United States | 1 | Recruiting | May 2027 | 60 |
| NCT07697456Crohn Disease · United States, Canada, Israel and more | 2 | Recruiting | Oct 2031 | 2,000 |
| NCT06632938Healthy Volunteer · China | 1 | Completed | May 15, 2025 | 24 |
| NCT06548542Crohn Disease · United States, Austria, Belgium and more | 2 | Recruiting | Jan 2030 | 590 |
| NCT06032546Disease · United States, Belgium, Brazil and more | 2 | Terminated | Sep 22, 2025 | 163 |
| NCT04554966Acquired Immunodeficiency Syndrome · United States, Puerto Rico | 1 | Completed | Aug 14, 2023 | 54 |
How it is read
Names in the registry
- “Trosunilimab”, 5 entries
- “ABBV-382”, 5 entries
Conditions, from the studies’ own filings
- Crohn Disease, 2 studies
- Acquired Immunodeficiency Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.